These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32438598)

  • 1. Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy.
    Papadaki C; Monastirioti A; Rounis K; Makrakis D; Kalbakis K; Nikolaou C; Mavroudis D; Agelaki S
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32438598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer.
    Monastirioti A; Papadaki C; Rounis K; Kalapanida D; Mavroudis D; Agelaki S
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.
    Yuwen D; Ma Y; Wang D; Gao J; Li X; Xue W; Fan M; Xu Q; Shen Y; Shu Y
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):163-173. PubMed ID: 30228154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
    Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
    Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.
    Gao W; Yu Y; Cao H; Shen H; Li X; Pan S; Shu Y
    Biomed Pharmacother; 2010 Jul; 64(6):399-408. PubMed ID: 20363096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
    Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
    Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.
    Monastirioti A; Papadaki C; Kalapanida D; Rounis K; Michaelidou K; Papadaki MA; Mavroudis D; Agelaki S
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1.
    Shi Q; Zhou Z; Ye N; Chen Q; Zheng X; Fang M
    Cancer Biomark; 2017 Dec; 20(4):539-546. PubMed ID: 28946554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
    Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
    BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.
    Wu C; Cao Y; He Z; He J; Hu C; Duan H; Jiang J
    Tohoku J Exp Med; 2014 Feb; 232(2):85-95. PubMed ID: 24531034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment.
    Xu X; Yu S; Sun W; Qin X; Chen Y; Zhou L; Lou R; Dong S; Shen B; Wu J; Zang J; Cao H; Shi M; Zhang Q; Feng J
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):431-438. PubMed ID: 29288364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
    Mei Y; Liu YB; Hu DL; Zhou HH
    Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
    PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.
    Yang X; Zhang Q; Zhang M; Su W; Wang Z; Li Y; Zhang J; Beer DG; Yang S; Chen G
    Int J Biol Sci; 2019; 15(8):1712-1722. PubMed ID: 31360113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential circulating miRNA signature for early detection of NSCLC.
    Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
    Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR.
    Markou A; Tsaroucha EG; Kaklamanis L; Fotinou M; Georgoulias V; Lianidou ES
    Clin Chem; 2008 Oct; 54(10):1696-704. PubMed ID: 18719201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
    Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
    Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.